Owning a signal
Start with the deceptively simple question of ownership and control of neural data. If your implant records your cortex, is that recording your property, the hospital's record, or the manufacturer's dataset? Property framings let you sell or license the data; rights framings (treating it as an inalienable part of the person, like an organ) resist commodification. Most regimes are converging on the middle path already described: classify it as special-category sensitive data and regulate its use tightly, rather than settling the metaphysics of who 'owns' it.
The reason the middle path wins is practical. Neural data is easily copied, aggregated, and re-derived, so a one-time transfer of 'ownership' would give little lasting protection. Governing use — purpose limitation, retention limits, a right to deletion (the Emotiv remedy) — protects the person on an ongoing basis regardless of who holds the bits.
Privacy by design: governance in the silicon
Some of the strongest protection is engineered, not legislated. Instead of shipping raw signals to a server, a system can run on-device (edge) decoding so that only the decoded command — not the underlying neural data — ever leaves the implant. Where models must be trained across many users, federated decoding keeps each person's data local and shares only model updates. And differential privacy adds calibrated noise so that no single individual's contribution can be reverse-engineered, enabling consent-preserving computation.
The (epsilon, delta)-differential-privacy guarantee: for any two datasets D, D' differing in one person's records and any set of outputs S, the mechanism's output distribution changes only slightly. Smaller epsilon means the presence of any one person is harder to detect — stronger privacy, usually at some cost in utility.
Consent for a device that evolves
The consent you gave at implantation cannot cover updates you could not foresee. Static, one-time consent is a poor fit for a device whose software, decoder, and even indications may change for years. The response is informed consent for evolving devices — a re-consenting relationship rather than a signature — which must also grapple with impaired decision-making capacity in some target populations and with therapeutic misconception, where a research participant overestimates the personal benefit of an experimental implant.
After the trial: abandonment and access
A quietly serious governance failure appears when studies end or companies fail. A participant can be left with an orphaned implant — hardware inside their body that no one will service or update. Ethical practice therefore requires attention to post-trial obligations and continued access and to responsible device abandonment and explantation planning, negotiated before implantation rather than after a sponsor walks away.
Equity
Finally, governance must ask who gets these devices at all. High-cost implants raise a stark question of equity of access: without deliberate policy, restorative and augmentative neurotech could widen existing health and social gaps rather than close them. Equity and access to neurotechnology therefore depends on reimbursement and coverage decisions as much as on any right written into a constitution — a right you cannot afford to exercise is not much of a right.